Citius Pharmaceuticals (CTXR)

• Market cap: $16.6M
• 1 day: -3.88%
• 5 days: -11.31%
• 1 month: -5.48%
• 3 months: -52.86%
• 6 months: -46.76%
• Year to date: -12.72%
• 1 year: -73.85%
• 5 years: -97.47%
• 10 years: -99.05%
• Sector: Healthcare
• Industry: Biotechnology

About: Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Employees: 23